OR WAIT null SECS
October 08, 2021
Pfizer and BioNTech’s request would make them the first vaccine accessible to individuals under the age of 12.
Moderna’s new facility is expected to produce 500 million vaccine doses per year.
October 07, 2021
FDA’s emergency use authorization will double rapid at-home COVID-19 testing capacity.
The $3 million investment will go towards various projects investigating key product attributes for therapeutic proteins.
The agency’s human medicines committee approved an additional site in West Point, Pa. in the United States for the manufacture of Janssen’s COVID-19 vaccine.
The agency has concluded that an extra dose of the COVID-19 vaccines may be given to those individuals with severely weakened immune systems.
The agency received a marketing authorization application a monoclonal antibody treatment for COVID-19 patients.
October 06, 2021
New excipients for protein-based drug products reduce viscosity while maintaining protein stability.
Moderna’s new 462,000-ft² science center is expected to be completed by 2023.
The collaboration between Sunovion, Sumitomo Dainippon, and Otsuka will focus on four compounds designed to treat neuropsychiatric health conditions.